Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGND) Debt to Equity (2016 - 2025)

Historic Debt to Equity for Ligand Pharmaceuticals (LGND) over the last 12 years, with Q3 2025 value amounting to $0.47.

  • Ligand Pharmaceuticals' Debt to Equity changed N/A to $0.47 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.47, marking a year-over-year change of. This contributed to the annual value of $0.13 for FY2022, which is N/A changed from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Debt to Equity stood at $0.47 for Q3 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' Debt to Equity peaked at $0.47 during Q3 2025, and registered a low of $0.09 during Q3 2022.
  • For the 3-year period, Ligand Pharmaceuticals' Debt to Equity averaged around $0.19, with its median value being $0.13 (2022).